{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T15:57:36Z","timestamp":1758124656504},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,4,18]],"date-time":"2018-04-18T00:00:00Z","timestamp":1524009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2018,4,18]],"date-time":"2018-04-18T00:00:00Z","timestamp":1524009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Delta-Fly Pharma"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2019,2,15]]},"DOI":"10.1007\/s10637-018-0602-0","type":"journal-article","created":{"date-parts":[[2018,4,18]],"date-time":"2018-04-18T02:09:35Z","timestamp":1524017375000},"page":"76-86","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Two phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules"],"prefix":"10.1007","volume":"37","author":[{"given":"Kamalesh","family":"Sankhala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris H.","family":"Takimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain C.","family":"Mita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Rod\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Mehrvarz Sarshekeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Burns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenzo","family":"Iizuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Kopetz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,4,18]]},"reference":[{"key":"602_CR1","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S1470-2045(02)00788-X","volume":"3","author":"CM Galmarini","year":"2002","unstructured":"Galmarini CM, Mackey JR, Dumontet C (2002) Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol 3:415\u2013424","journal-title":"Lancet Oncol"},{"key":"602_CR2","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","volume":"15","author":"HA Burris 3rd","year":"1997","unstructured":"Burris HA 3rd, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403\u20132413","journal-title":"J Clin Oncol"},{"key":"602_CR3","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1200\/JCO.2000.18.1.122","volume":"18","author":"AB Sandler","year":"2000","unstructured":"Sandler AB, Nemunaitis J, Denham C et al (2000) Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 18:122\u2013130","journal-title":"J Clin Oncol"},{"key":"602_CR4","first-page":"4417","volume":"50","author":"LW Hertel","year":"1990","unstructured":"Hertel LW, Boder GB, Kroin JS et al (1990) Evaluation of the antitumor activity of gemcitabine (2\u2032,2\u2032-difluoro-2\u2032-deoxycytidine). Cancer Res 50:4417\u20134422","journal-title":"Cancer Res"},{"key":"602_CR5","first-page":"6110","volume":"51","author":"P Huang","year":"1991","unstructured":"Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W (1991) Action of 2\u2032,2\u2032-difluorodeoxycytidine on DNA synthesis. Clin Cancer Res 51:6110\u20136117","journal-title":"Clin Cancer Res"},{"key":"602_CR6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/j.1349-7006.2004.tb03189.x","volume":"95","author":"A Matsuda","year":"2004","unstructured":"Matsuda A, Sasaki T (2004) Antitumor activity of sugar-modified cytosine nucleosides. Cancer Sci 95:105\u2013111","journal-title":"Cancer Sci"},{"key":"602_CR7","doi-asserted-by":"publisher","first-page":"4183","DOI":"10.1021\/jm00078a006","volume":"36","author":"A Azuma","year":"1993","unstructured":"Azuma A, Nakajima Y, Nishizono N et al (1993) Nucleosides and nucleotides. 122. 2\u2032-C-cyano-2\u2032-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum. J Med Chem 36:4183\u20134189","journal-title":"J Med Chem"},{"key":"602_CR8","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1021\/jm00017a023","volume":"38","author":"A Azuma","year":"1995","unstructured":"Azuma A, Hanaoka K, Kurihara A et al (1995) Nucleosides and nucleotides. 141. Chemical stability of a new antitumor nucleoside, 2\u2032-C-cyano-2\u2032-deoxy-1-beta-D-arabino- pentofuranosylcytosine in alkaline medium: formation of 2\u2032-C-cyano-2\u2032-deoxy-1-beta-D-ribo- pentofuranosylcytosine and its antitumor activity. J Med Chem 38:3391\u20133397","journal-title":"J Med Chem"},{"key":"602_CR9","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1124\/mol.59.4.725","volume":"59","author":"A Azuma","year":"2001","unstructured":"Azuma A, Huang P, Matsuda A, Plunkett W (2001) 2\u2032-C-cyano-2\u2032-deoxy-1-beta-D-arabino-pentofuranosylcytosine: a novel anticancer nucleoside analog that causes both DNA strand breaks and G(2) arrest. Mol Pharmacol 59:725\u2013731","journal-title":"Mol Pharmacol"},{"key":"602_CR10","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1080\/15257779508012407","volume":"14","author":"A Matsuda","year":"1995","unstructured":"Matsuda A, Azuma A (1995) 2\u2032-C-Cyano-2\u2032-deoxy-1-\u03b2-D-arabinofuranosylcytosine (CNDAC): A mechanism-based DNA-strand-breaking antitumor nucleoside. Nucleosides Nucleotides 14:461\u2013471","journal-title":"Nucleosides Nucleotides"},{"key":"602_CR11","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/(SICI)1097-0215(19990719)82:2<226::AID-IJC13>3.0.CO;2-X","volume":"82","author":"K Hanaoka","year":"1999","unstructured":"Hanaoka K, Suzuki M, Kobayashi T et al (1999) Antitumor activity and novel DNA-self-strand-breaking mechanism of CNDAC (1-(2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl) cytosine) and its N4-palmitoyl derivative (CS-682). Int J Cancer 82:226\u2013236","journal-title":"Int J Cancer"},{"key":"602_CR12","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"602_CR13","unstructured":"Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS. March 31, 2003 (http:\/\/ctep.cancer.gov), Publish Date: August 9, 2006"},{"issue":"1","key":"602_CR14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/00008571-200301000-00005","volume":"13","author":"L Yue","year":"2003","unstructured":"Yue L, Saikawa Y, Ota K et al (2003) A functional single-nucleotide polymorphism in the human cytidine deaminase gene contributing to ara-C sensitivity. Pharmacogenetics 13(1):29\u201338","journal-title":"Pharmacogenetics"},{"key":"602_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1093\/mutage\/18.1.45","volume":"18","author":"A Hartmann","year":"2003","unstructured":"Hartmann A, Agurell E, Beevers C et al (2003) Recommendations for conducting the in vivo alkaline Comet assay. 4th International Comet Assay Workshop. Mutagenesis 18:45\u201351","journal-title":"Mutagenesis"},{"key":"602_CR16","doi-asserted-by":"publisher","first-page":"86","DOI":"10.2307\/3577587","volume":"122","author":"PL Olive","year":"1990","unstructured":"Olive PL, Ban\u00e1th JP, Durand RE (1990) Heterogeneity in radiation-induced DNA damage and repair in tumor and normal cells measured using the \"comet\" assay. Radiat Res 122:86\u201394","journal-title":"Radiat Res"},{"key":"602_CR17","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s10637-006-8219-0","volume":"24","author":"J Gilbert","year":"2006","unstructured":"Gilbert J, Carducci MA, Baker SD, Dees EC, Donehower R (2006) A Phase I study of the oral antimetabolite, CS-682, administered once daily 5 days per week in patients with refractory solid tumor. Investig New Drugs 24:499\u2013508","journal-title":"Investig New Drugs"},{"key":"602_CR18","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s10637-006-5392-0","volume":"24","author":"T Delaunoit","year":"2006","unstructured":"Delaunoit T, Burch PA, Reid JM et al (2006) A phase I clinical and pharmacokinetic study of CS-682 administered orally in advanced malignant solid tumors. Investig New Drugs 24:327\u2013333","journal-title":"Investig New Drugs"},{"key":"602_CR19","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1158\/1078-0432.CCR-04-1497","volume":"11","author":"K Yonemori","year":"2005","unstructured":"Yonemori K, Ueno H, Okusaka T et al (2005) Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin. Clin Cancer Res 11:2620\u20132624","journal-title":"Clin Cancer Res"},{"key":"602_CR20","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1200\/JCO.2006.06.7405","volume":"25","author":"E Sugiyama","year":"2007","unstructured":"Sugiyama E, Kaniwa N, Kim SR et al (2007) Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J Clin Oncol 25:32","journal-title":"J Clin Oncol"},{"issue":"5","key":"602_CR21","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/sj.tpj.6500259","volume":"4","author":"AK Fukunaga","year":"2004","unstructured":"Fukunaga AK, Marsh S, Murry DJ, Hurley TD, McLeod HL (2004) Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway. Pharmacogenomics J 4(5):307\u2013314","journal-title":"Pharmacogenomics J"},{"issue":"2","key":"602_CR22","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1158\/0008-5472.CAN-03-2456","volume":"64","author":"Y Ge","year":"2004","unstructured":"Ge Y, Jensen TL, Stout ML et al (2004) The role of cytidine deaminase and GATA1 mutations in the increased cytosine arabinoside sensitivity of Down syndrome myeloblasts and leukemia cell lines. Cancer Res 64(2):728\u2013735","journal-title":"Cancer Res"},{"issue":"4","key":"602_CR23","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1046\/j.1365-2141.1998.01084.x","volume":"103","author":"JK Schr\u00f6der","year":"1998","unstructured":"Schr\u00f6der JK, Kirch C, Seeber S, Sch\u00fctte J (1998) Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukemia. Br J Haematol 103(4):1096\u20131103","journal-title":"Br J Haematol"},{"issue":"9","key":"602_CR24","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1158\/1078-0432.CCR-04-1781","volume":"11","author":"M Ogawa","year":"2005","unstructured":"Ogawa M, Hori H, Ohta T, Onozato K, Miyahara M, Komada Y (2005) Sensitivity to gemcitabine and its metabolizing enzymes in neuroblastoma. Clin Cancer Res 11(9):3485\u20133493","journal-title":"Clin Cancer Res"},{"issue":"7","key":"602_CR25","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/S0145-2126(01)00184-9","volume":"26","author":"CM Galmarini","year":"2002","unstructured":"Galmarini CM, Thomas X, Calvo F et al (2002) Potential mechanisms of resistance to cytarabine in AML patients. Leuk Res 26(7):621\u2013629","journal-title":"Leuk Res"},{"issue":"7","key":"602_CR26","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1093\/carcin\/12.7.1253","volume":"12","author":"RJ Parker","year":"1991","unstructured":"Parker RJ, Gill I, Tarone R et al (1991) Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry. Carcinogenesis 12(7):1253\u20131258","journal-title":"Carcinogenesis"},{"issue":"3","key":"602_CR27","first-page":"507","volume":"5","author":"JM Hartley","year":"1999","unstructured":"Hartley JM, Spanswick VJ, Gander M et al (1999) Measurement of DNA cross-linking in patients on ifosfamide therapy using the single cell gel electrophoresis (comet) assay. Clin Cancer Res 5(3):507\u2013512","journal-title":"Clin Cancer Res"},{"issue":"1","key":"602_CR28","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/tcm.1035","volume":"22","author":"N Kopjar","year":"2002","unstructured":"Kopjar N, Garaj-Vrhovac V, Milas I (2002) Assessment of chemotherapy-induced DNA damage in peripheral blood leukocytes of cancer patients using the alkaline comet assay. Teratog Carcinog Mutagen 22(1):13\u201330","journal-title":"Teratog Carcinog Mutagen"},{"issue":"9","key":"602_CR29","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1158\/1078-0432.CCR-04-2353","volume":"11","author":"ER Plummer","year":"2005","unstructured":"Plummer ER, Middleton MR, Jones C et al (2005) Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1. Clin Cancer Res 11(9):3402\u20133409","journal-title":"Clin Cancer Res"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-018-0602-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-018-0602-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-018-0602-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:27:21Z","timestamp":1678559241000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-018-0602-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,18]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2,15]]}},"alternative-id":["602"],"URL":"https:\/\/doi.org\/10.1007\/s10637-018-0602-0","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,18]]},"assertion":[{"value":"22 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare no potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent to participate in the study was obtained from each patient before study enrollment and the performance of any study-specific procedures.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}